Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy.
about
The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergyLenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.Toll-like Receptors in Chronic Lymphocytic Leukemia.Neutrophils from chronic lymphocytic leukemia patients exhibit an increased capacity to release extracellular traps (NETs).
P2860
Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy.
@en
type
label
Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy.
@en
prefLabel
Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy.
@en
P921
P1476
Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy
@en
P2093
John C Riches
John G Gribben
P304
P356
10.2174/138161212801227023
P577
2012-01-01T00:00:00Z